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Idiopathic interstitial pneumonias are diseases of the lung interstitium where the etiology is unknown.
They constitute the largest group of interstitial lung diseases. Making a diagnosis can be challenging due
to the diversity of clinical presentations and frequently, non-speciﬁc radiological and pathological
ﬁndings. The most common form, idiopathic pulmonary ﬁbrosis, has a poor prognosis with median
survival of 3 years from diagnosis. There have been changes in the nomenclature of different individual
entities over the years. Moreover, there is paucity of data on the best treatments available to manage this
group of lung diseases. The nomenclature, clinical features, pathophysiology, diagnostic techniques, and
prognosis of the idiopathic interstitial pneumonias are discussed in this review.
 2009 Elsevier Ltd. All rights reserved.Educational objectives
 To understand the nomenclature of the idiopathic interstitial
pneumonias (IIPs).
 To review the pathophysiology and clinical features of IIPs.
 To illustrate the importance of high resolution computed
tomography (HRCT), transbronchial lung biopsy (TBB) and
video assisted thoracoscopic surgical (VATS) biopsy in the
diagnosis of this group of lung diseases.
 To evaluate the diagnostic utility of bronchoalveolar lavage
(BAL) in diagnosing different IIPs.
 To discuss the prognosis of IIPs.1. Introduction
Idiopathic interstitial pneumonias (IIPs) are a diverse group of
diseases of the lung parenchyma with variable prognoses. Despite
advancements in diagnostic techniques and improvement in
diagnostic yield, there has been little success in improving overall
survival. Historically, there have been several different classiﬁca-
tions such as those proposed by Liebow and Carrington1 (1969),
Mu¨ller and Colby2 (1997), and Katzenstein3 (1997). The most recent
and comprehensive update on nomenclature has been the ATS/ERS
international multidisciplinary consensus classiﬁcation4 (Fig. 1). It
deﬁnes certain histologic patterns which form the basis for clinico–
radiologic–pathologic diagnosis of individual entities of IIPs.: þ44 1482624068.
Fahim), s.hart@hull.ac.uk
All rights reserved.2. Usual interstitial pneumonia (UIP)/idiopathic pulmonary
ﬁbrosis (IPF)
Usual interstitial pneumonia (UIP) is the histological counter-
part of idiopathic pulmonary ﬁbrosis (IPF), which has also been
called cryptogenic ﬁbrosing alveolitis (CFA) in the UK and Europe.
This disease has an estimated prevalence of 14–43 per 100,000 and
an estimated yearly incidence of 7–16 per 100,000.5 It is the most
common form of IIP and carries the worst prognosis. Smoking has
been associated with IPF but the exact association between
smoking and clinical outcome in IPF is not absolutely clear. Recently
a retrospective study6 suggested that smokers have milder disease
as compared to ex-smokers, but survival is better in non-smokers
with IPF when compared to former smokers or combined group of
former and current smokers.
The usual clinical presentation of IPF is with insidious onset of
breathlessness, ﬁne basal crackles on lung auscultation, type 1
respiratory failure, and a restrictive ventilatory defect. The clinical
course is often slowly progressive leading to death after several
years, but some patients may remain stable for many years until an
‘‘exacerbation’’ or an accelerated phase ensues with a rapid dete-
rioration which is frequently fatal.
The chest radiograph (Fig. 2a) typically shows diffuse lower zone
reticular opacities with volume loss. Advancement in the image
quality and reﬁnement of HRCT slices have made a great impact on
our understanding of IPF on radiological grounds, and HRCT scan
(Fig. 2b) is more sensitive than chest radiography in diagnosing
early IPF. Typically there are areas of bilateral peripheral and sub-
pleural reticular abnormalities without signiﬁcant ground glass
shadowing. Areas of honeycombing with traction bronchiectasis
are in a basal distribution initially, which progresses to involve all
lobes in later stages. In the presence of extensive ground glass
Fig. 2. (a) Chest radiograph showing diffuse interstitial inﬁltrates in IPF. (b) HRCT scan
demonstrating subpleural reticulation with honeycombing without signiﬁcant ground
glass change, highly suggestive of usual interstitial pneumonia (UIP). (c) Lung biopsy
showing heterogeneous areas of architectural distortion with ﬁbrosis and ﬁbroblastic
foci (arrow) along with normal lung parenchyma consistent with usual interstitial
pneumonia (UIP).
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Fig. 1. Classiﬁcation of idiopathic interstitial pneumonias. NSIP non-speciﬁc interstitial
pneumonia; COP cryptogenic organising pneumonia; DIP desquamative interstitial
pneumonia; RB-ILD respiratory bronchiolitis interstitial lung disease; LIP lymphoid
interstitial pneumonia; and AIP acute interstitial pneumonia.
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effort should be made to obtain histology.
Pulmonary function tests demonstrate a restrictive ventilatory
defect with reduced gas transfer. The lung volumes are usually
small but there may be mixed picture of obstructive and restrictive
impairment in the presence of co-existing emphysema. PFTs are
helpful in determining disease severity and hence prognosis at
presentation, with a Tlco< 40% predicted or desaturation during
a six-minute walk indicating severe disease. Serial PFTs are the best
way of monitoring changes in IPF, a>10% fall in FVC being a reliable
indicator of disease progression.
Histologically, UIP manifests as heterogeneous areas of ﬁbrosis,
architectural distortion and honeycombing with minimal intersti-
tial inﬂammatory changes. Characteristically, there are patches of
ﬁbroblasts, myoﬁbroblasts and newly formed collagen, called
ﬁbroblastic foci (Fig. 2c) seen on histology. There is recent evidence
that these ﬁbroblastic foci are in fact part of a complex architecture
which is highly interconnected and extends from pleura to the
underlying lung parenchyma, reﬂecting a reactive process in UIP.7
3. Acute exacerbation of IPF (AE-IPF)
In 1993, Kondoh et al.8 described 3 cases of IPF with acute
clinical deterioration and progressive hypoxia. There were no
identiﬁable infecting agents. Subsequently, acute exacerbation of
IPF has been increasingly recognised although the precise incidence
is unknown. The criteria9 used for the diagnosis of AE-IPF have been
reﬁned and include (1) acute worsening of dyspnea over less than
a month’s duration (2) new pulmonary inﬁltrates on chest radio-
graph or CT scan (3) worsening hypoxemia and (4) absence of an
identiﬁable cause including infection or cardiovascular disease.
HRCT scan typically shows diffuse ground glass change super-
imposed on background peripheral reticulation and/or honey-
combing consistent with UIP. It can be challenging to differentiate
AE-IPF from infection as the clinico-radiological features do overlap
and many patients receive broad-spectrum antibiotics for
presumed bacterial pneumonia. This diagnosis is particularly
challenging in patients without a prior diagnosis of IPF, when
respiratory failuremakes bronchoscopy, BAL or lung biopsy difﬁcult
or impossible. If histology is obtained, the most common histo-
logical pattern is diffuse alveolar damage on an underlying UIP
pattern. However, organising pneumonia has been reported with
a favourable response to corticosteroids.10
Fig. 3. (a) Chest radiograph showing bilateral reticulo-nodular shadowing in a patient
with ﬁbrotic NSIP. (b) HRCT scan showing diffuse involvement of lung parenchyma
with bilateral honeycomb change and associated ground glass attenuation suggestive
of ﬁbrotic NSIP. (c) Diffuse areas of interstitial inﬂammation and ﬁbrosis in a uniform
pattern on histology, diagnostic of NSIP.
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Many different mechanisms have been proposed to try to
explain the pathophysiology of IPF. Historically, IPF was believed to
be an inﬂammatory disorder but this hypothesis has been chal-
lenged for a number of reasons. First, inﬂammation is not a prom-
inent histopathologic ﬁnding. Second, IPF does not respondwell (or
at all) to anti-inﬂammatory treatment in the form of corticosteroids
or other immunosuppressives. Third, epithelial injury can lead to
pulmonary ﬁbrosis even in the absence of signiﬁcant ongoing
inﬂammation.11 It is nowwidely believed that injury to the alveolar
epithelial cells is the ﬁrst insult in the pathogenesis of IPF, but the
exact nature of the cellular injury has yet to be identiﬁed. However,
epithelial injury may by immunological (either antibody or cell-
mediated), chemical (e.g., reﬂux of gastric contents), microbial, or
particulate (organic or inorganic). There is evidence to support each
of these possibilities, which has been reviewed elsewhere. Trans-
formation of epithelial cells into ﬁbroblasts [epithelial mesen-
chymal transition (EMT)] is an attractive explanation for the
preponderance of ﬁbroblasts in the lung in IPF. Production and
activation of the pro-ﬁbrotic cytokine TGF-ß are thought to be
a cardinal feature in pulmonary ﬁbrosis.12 Activation of protease
activated receptors by the coagulation cascade has also received
much attention as a driver of ﬁbroblast proliferation and
activation.13
There has been much interest in how certain genetic differences
might predispose to IPF. For example, we have shown that the NA1/
NA2 polymorphism of the IgG receptor CD16B is associated with
IPF, supporting a role for an underlying immunological insult
(Bournazos et al., submitted). Gene expression proﬁling has shown
that there are clearly different gene signatures in IPF patients
compared to normal controls. Zuo and co-workers14 found that the
genes encoding extracellular matrix formation and degradation
were signiﬁcantly increased in ﬁbrotic lungs, the most distinctive
being matrix metalloproteinase-7 (MMP-7). The only clearly
deﬁned genetic mutations in association with IPF are in the gene
encoding surfactant protein C (SFTPC) and telomerase genes hTERT
and TERC.15–17 Selman and colleagues18 looked at gene expression
proﬁles of 114 patients with IPF and found that adenosine 2B
receptor and prominin-1/CD133 genes were over expressed in the
rapidly progressive variant. Moreover, it may be possible to
distinguish between familial and idiopathic forms of idiopathic
interstitial pneumonias on the basis of gene expression.19
5. Non-speciﬁc interstitial pneumonia (NSIP)
Non-speciﬁc interstitial pneumonia (NSIP) is a histological diag-
nosis. Despite its unfortunate name, idiopathic NSIP is regarded as
a distinct disease entity characterized by homogenous lung ﬁbrosis
thathas abetterprognosis than IPF. In the2002ATS/ERS international
multidisciplinary consensus classiﬁcation,4 idiopathic NSIP was
classiﬁed as a provisional diagnosis rather than a speciﬁc disease
entity. However, recently a report of American Thoracic Society
project20 concluded that idiopathic NSIP is a speciﬁc disease entity
that occurs mostly in middle-aged women who are never-smokers.
Here we focus on idiopathic NSIP, bearing in mind that the histo-
logicalpictureofNSIPmayalsobe found inconnective tissuediseases,
HIV infection, drug reactions, and hypersensitivity pneumonitis.
The clinical presentation of NSIP is oftenwith sub-acute onset of
breathlessness. The chest radiograph (Fig. 3a) shows interstitial
inﬁltrates while HRCT scan (Fig. 3b) typically shows areas of ground
glass attenuation with or without signiﬁcant honeycombing and
the distribution of lung parenchymal involvement is rather more
uniform than IPF. However, it can be extremely challenging to
differentiate ﬁbrotic NSIP from IPF on clinico-radiological grounds.
Fig. 4. (a) Bilateral patchy consolidation in lower zones on chest radiograph in
cryptogenic organizing pneumonia (COP). (b) CT thorax depicting patchy areas of
pulmonary inﬁltrates with associated bronchiectasis. The lung biopsy was suggestive
of organizing pneumonia. (c) Histology from a patient with COP demonstrating
Masson bodies (arrows) and inﬂammatory inﬁltrate with preservation of lung
architecture.
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mixed patterns. Fibrotic NSIP is by far the most common, and is
characterized by homogenous areas of interstitial ﬁbrosis with
minimal inﬂammation (Fig. 3c). Fibroblastic foci are an infrequent
feature. Cellular NSIP is characterized by inﬂammatory inﬁltrate
without ﬁbrosis and has the best prognosis out of all three
categories.
With regards to prognosis, NSIP has a better prognosis than
UIP.21–23 In view of signiﬁcantly different clinical outcome, it is
critical to obtain histological diagnosis when HRCT shows features
suggestive of NSIP.
6. Cryptogenic organising pneumonia (COP)
Cryptogenic organising pneumonia is a distinct disease entity of
unknown cause described by Davison and colleagues in 1983.24 It is
characterized by proliferation of granulation tissue in alveolar
spaces and sometimes bronchioles. It has also been known as
idiopathic bronchiolitis obliterans organising pneumonia (BOOP),
a term which does not reﬂect the true histopathological pattern of
organising pneumonia. BOOP is not a recommended terminology to
be used for COP as bronchioles are not always involved and it can
easily be confused with obliterative bronchiolitis (OB), which is
a completely different disease.
COP usually presents with relatively short duration of dyspnea
with dry or productive cough. Patients may have fever, sweats,
weight loss and myalgia, and laboratory tests typically show
increased CRP (C reactive protein), ESR (erythrocyte sedimentation
rate) and peripheral blood neutrophilia.25 The presenting features
are often indistinguishable from lung infection, so patients are
frequently treated with multiple courses of antibiotics, and the
diagnosis of COP is raised when the pneumonia fails to resolve, or
when it relapses.
COP can be subdivided into three variants according to prog-
nosis. Typical COP is associated with good overall prognosis with
spontaneous remission in about 50% of cases in most case
series.26–29 Acute fulminant COP presents with features of acute
respiratory distress syndrome (ARDS) and frequently needs
mechanical ventilatory support. This rare variant is occasionally
fatal without progressing to overt ﬁbrosis. The biopsy shows
features typical of organising pneumonia. It might pose a chal-
lenge to distinguish it from acute interstitial pneumonia on clinical
and radiological grounds. Fibrosing COP is a rare subset of COP
where clinical outcome is variable. There is usually mild interstitial
ﬁbrosis which is non-progressive in nature. Moreover there is
evidence that some cases might lead to rapid progression of
respiratory failure and death as described by case series of 10
patients by Cohen and colleagues.30
The most common radiographic features are unilateral or
bilateral areas of patchy consolidation (Fig. 4a). CT scan (Fig. 4b)
typically shows areas of airspace consolidation31,32 with air bron-
chograms. The distribution of parenchymal abnormality is usually
peribronchial or subpleural with propensity to involve basal zones
of the lung. There may be ground glass attenuation present in
approximately 60% of cases with COP.4
The histology (Fig. 4c) shows patchy ﬁbroblastic plugs within
the alveoli, called Masson bodies. There is minimal architectural
distortion and frequently, there is an associated inﬂammatory
inﬁltrate with aggregates of foamy macrophages, but a paucity of
honeycomb change or severe ﬁbrosis. It must be emphasised that
this histological appearance of organising pneumonia may occur in
many other conditions, including bacterial and viral infection and
in areas of other ILDs including UIP. A conﬁdent diagnosis of COP
illustrates the importance of clinical and radiological ﬁndings in
addition to histology, and particularly exclusion of infection.
Fig. 5. (a) Chest radiograph with bilateral ground glass shadowing and ill-deﬁned
opacities. (b) HRCT showing extensive ground glass shadowing without honeycombing
in a diffuse pattern affecting all lobes in DIP. (c) VATS biopsy showing evidence of
accumulation of alveolar macrophages (arrows) with a focal inﬂammatory cell
inﬁltrate and mild interstitial ﬁbrosis, diagnostic of DIP.
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Respiratory bronchiolitis, ﬁrst described in 1974 as a distinct
histopathologic entity, is characterized by the presence of pig-
mented macrophages in respiratory bronchioles exclusively in
cigarette smokers. It is almost always asymptomatic in all cases.
A small proportion of patients with respiratory bronchiolitis
develop a clinical entity called RB-ILD, which presents with
symptoms of dyspnea and cough. The majority of cases have mild
symptoms which are non-progressive. RB-ILD and DIP are believed
to represent two ends of the same clinico-pathological spectrum as
both conditions share many clinical and histological features. It
typically affects males in their fourth or ﬁfth decadewith a smoking
history of 30 pack-years or more.
The chest radiograph may show reticular or reticulo-nodular
shadowing in a bibasal distribution. The CT scan reveals cen-
trilobular nodule formation, bronchial wall thickening and occa-
sionally ground glass attenuation. There is often centrilobular
emphysema associated with these changes. Pulmonary function
tests reveal mild to moderate reduction in gas transfer. There may
be an isolated increase in residual volume33 and mixed obstructive
and restrictive ventilatory defects.
On histology, there is accumulation of pigmented brown
macrophages in respiratory bronchioles, alveolar ducts and peri-
bonchiolar alveolar spaces. A fairly conﬁdent diagnosis of RB-ILD
can often be made on history and HRCT ﬁndings; hence a lung
biopsy is not required in the majority of cases.
8. Desquamative interstitial pneumonia (DIP)
Desquamative interstitial pneumonia is a rare IIP, typically
affecting smokers in their fourth or ﬁfth decade of life. It was
originally described by Liebow and colleagues34 as they believed
that there was desquamation of alveolar epithelial cells in this
disease. However, it is now recognised that the histopathological
hallmark is diffuse accumulation of pigmented macrophages in
alveolar air spaces rather than desquamation of epithelium. A more
accurate term would be ‘alveolar macrophage pneumonia’ but in
view of rarity of this condition, the term DIP was retained in the
ATS/ERS consensus classiﬁcation.4
The chest radiograph is not very sensitive to detect DIP but may
show widespread ground glass haziness (Fig. 5a). HRCT scan
(Fig. 5b) typically reveals ground glass opaciﬁcation with or
without reticulation and honeycombing fairly similar to NSIP. There
is lower zone predominance and the pattern of interstitial abnor-
malities is diffuse and uniform in contrast to UIP. Lung biopsy
(Fig. 5c) shows presence of intra-alveolar macrophages and mild
interstitial ﬁbrosis with chronic inﬂammatory cell inﬁltrate. DIP is
distinguished from RB-ILD by the lack of bronchiolocentric distri-
bution. The prognosis of DIP is generally good, with 70% survival
after 10 years.35
9. Lymphoid interstitial pneumonia (LIP)
Lymphoid interstitial pneumonia was the term originally used
by Liebow and Carrington in 1966 to describe a histopathologic
entity with diffuse lymphocytic inﬁltration of pulmonary inter-
stitium. It can occur in association with connective tissue diseases,
autoimmune diseases such as pernicious anaemia and chronic
active hepatitis, HIV, and hypogammaglobulinemia, particularly
common variable immune deﬁciency. Previously, it was considered
to be a pre-malignant entity that transformed into lymphoma, but
there is no robust evidence that LIP has a malignant potential;
hence it is included in the classiﬁcation of IIPs as a distinct entity.
The pathogenesis of LIP is considered to be autoimmune in view of
Table 1
ATS/ERS criteria for diagnosis of IPF in the absence of surgical lung biopsy.
Major criteria Minor criteria
Exclusion of known causes of ILD Age> 50 years
Abnormal lung function tests showing
restrictive ventilatory defect with
impaired gas exchange
Insidious onset of otherwise
unexplained dyspnea on exertion
Bibasal reticulation with minimal ground
glass change on HRCT scan
Duration of illness> 3 months
Transbronchial lung biopsy or BAL showing no
features to support an alternative diagnosis
Bibasal inspiratory
crackles(dry or velcro type)
A. Fahim, S.P. Hart / Respiratory Medicine CME 2 (2009) 55–6260strong association with many autoimmune diseases such as Sjog-
ren’s syndrome. Moreover, there is a possibility of an infectious
etiology as LIP is seen in associationwith EBV36 (Epstein Barr virus),
HIV and Human T-lymphotropic virus type I (HTLV-I).37
Clinically, it presents with gradual onset of breathlessness and
cough with a female predominance of 2:1, usually in the 4–7th
decade of life. HRCT scan reveals areas of ground glass shadowing
with interstitial thickening and formation of cysts in perivascular
regions. Honeycomb change is rare in LIP.
Surgical lung biopsy is required to conﬁdently make the diag-
nosis and histology shows diffuse interstitial inﬁltration by
lymphocytes, plasma cells and histiocytes with increase in macro-
phages and type 2 epithelial cell hyperplasia. The mortality in LIP
has been reported to be 38% in two observational studies38,39
consisting of 26 patients. In these small studies 25% of cases
showed rapid improvement, 15% showed mild improvement, and
25% remained stable. The mortality in these studies was predomi-
nantly related to progression of ﬁbrosis and infections complicating
immunosuppressive therapy.
10. Acute interstitial pneumonia (AIP)
AIP was ﬁrst described by Hamman and Rich in 1935 and
presents as a rapidly progressive form of interstitial lung disease
with type 1 respiratory failure. It is histologically characterized by
diffuse alveolar damage and formation of hyaline membranes.
Neutrophil mediated injury is believed to play an important part in
pathogenesis of AIP. The clinical, radiological, and histological
features are similar to the acute respiratory distress syndrome
(ARDS), and AIP may be considered to be idiopathic ARDS.
AIP tends to occur in previously healthy individuals. There is
fairly short history of dyspnea and associated cough and fever with
bilateral radiological inﬁltrates on chest radiograph and CT scan.
There are bilateral crackles and patients are severely hypoxemic
despite supplemental oxygen. HRCT scan shows bilateral areas of
ground glass shadowing and patchy airspace consolidation.
Moreover, there may be traction bronchiectasis and extensive
reticulation in later stages. Many cases need mechanical ventila-
tion, and even with the ventilatory support the mortality is
extremely high (>50%).Table 2
Bronchoalveolar lavage ﬁndings in different idiopathic interstitial pneumonias.
Disease entity Cellular proﬁle Other features
Idiopathic pulmonary
ﬁbrosis
Neutrophils þþþ
Lymphocytes þ
Eosinophils þ
Neutrophils/ disease extent
Eosinophils/ disease
progressiveness
Cryptogenic
organizing pneumonia
Neutrophils þ
Lymphocytes þ
Eosinophils þ
Foamy macrophages
Y CD4þ/CD8 ratio
Non-speciﬁc
interstitial pneumonia
Lymphocytes þ
Eosinophils þ
Eosinophilia is associated with
increased mortality in SSc
related NSIP11. Role of lung biopsy in the diagnosis of IIPs
Lung biopsy plays a key role in the diagnosis and management
of IIPs. It may be in the form of a transbronchial (bronchoscopic)
lung biopsy (TBLB), or surgical lung biopsy.
TBLB is performed through a ﬂexible ﬁberoptic bronchoscope
and has a limited role in the diagnosis of IIPs. The site for trans-
bronchial biopsy is guided by HRCT scan and generally 4–6 biopsy
samples are recommended.40,41 The biopsies are taken from areas
of radiological abnormality adjacent to normal lung and avoiding
parts of the lung with honeycomb change. The lingula and right
middle lobes tend to provide limited diagnostic information, so
these areas should not be the preferred sites to biopsy. The main
limitation of TBLB is the small size of specimens obtained leading to
poor diagnostic yield in most IIPs.
In the majority of patients with IIPs, surgical lung biopsy is
required if the diagnosis is not apparent on clinical and radiological
grounds. It has an extremely good diagnostic yield of >90% with
a low mortality.42 The method of choice is video assisted thoraco-
scopic surgical (VATS) biopsy, which is a safe procedure without
signiﬁcant short-term mortality43 and with a shorter hospital stay
and reduced analgesic requirements when compared with open
lung biopsy (OLB).44 The main complications are post-operative
pain and persistent air leak. A surgical lung biopsy can be especially
valuable in distinguishing between UIP and ﬁbrotic NSIP with an
IPF-like clinical/radiological proﬁle. Moreover, ATS/ERS criteria45
(Table 1) are a useful means to diagnose IPF in the absence of
surgical lung biopsy. The likelihood of correct diagnosis of IPF is
increased in the presence of all major and at least 3 of the four
minor criteria.
The decision to perform a surgical lung biopsy should be made
after multidisciplinary (clinician/radiologist/surgeon/pathologist)
consensus and a frank discussion with appropriately informed
patient where the results of the biopsy would provide valuable
diagnostic and prognostic information.12. Role of bronchoalveolar lavage in the diagnosis of IIPs
There is limited data on the role of bronchoalveolar lavage (BAL)
in the diagnosis and to determine prognosis and need for treatment
in the different IIPs. Its utility is predominantly limited to a research
tool to examine immune effector cells accumulating at the alveolar
level. There are certain conditions where BAL may contribute
important additional diagnostic information when combined with
clinical features and HRCT ﬁndings. These include eosinophilic
pneumonia, alveolar proteinosis,46 opportunistic infection, and
malignancy.
The most common cell types in BAL seen in different IIPs are
summarised in Table 2.13. Conclusion
In summary, idiopathic interstitial pneumonias pose a diag-
nostic challenge to pulmonologists, radiologists and pathologists. It
is extremely important to have a multidisciplinary approach in
diagnosing this group of interstitial lung diseases with variable
prognoses. Lung biopsy provides valuable information in many
cases and should be undertaken if clinico-radiological correlation is
insufﬁcient to make a conﬁdent diagnosis.Conﬂicts of interests statement
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CME section
This article has been accredited for CME learning by the Euro-
pean Board of Accreditation in Pneumology (EBAP). You can receive
one CME credit by successfully answering these questions online.
a) Visit the journal CME site at http://www.resmedcme.com
b) Complete the answers online, and receive your ﬁnal score upon
completion of the test.
c) Should you successfully complete the test, you may download
your accreditation certiﬁcate (subject to an administrative
charge).Educational questions:
Answer the following questions:
1. Which one of the following is NOT a feature of idiopathic
pulmonary ﬁbrosis?
a. Presence of ﬁbroblastic foci on histology
b. Heterogenous areas of architectural distortion
c. Honeycombing with minimal ground glass change on HRCT
d. Extensive ground glass shadowing and dense consolidation
on HRCT
e. Subpleural and peripheral distribution of abnormalities
2. Which one of these is a histological feature of desquamative
interstitial pneumonia?
a. Desquamation of alveolar epithelial cells
b. Accumulation of alveolar macrophages
c. Extensive ﬁbrosis with honeycombing
d. Hemosiderin pigment laden-macrophages brightly staining
with Prussian blue
e. Formation of hyaline membranes
3. Regarding the lung biopsy in idiopathic interstitial pneumo-
nias, select the correct statement:
a. Transbronchial biopsy is the biopsy of choice
b. VATS biopsy has better diagnostic yield than open lung
biopsy
c. Lung biopsy always provides the unifying diagnosis in IIPs
d. The suitable biopsy site should be guided by HRCT scan
e. Lingula andmiddle lobe are themost suitable sites to biopsy
4. Which of the following is NOT true regarding acute interstitial
pneumonia?
a. Histology shows formation of hyaline membranes
b. Neutrophilmediated injuryplaysno role in thepathogenesis
c. It is also known as Hamman–Rich syndrome
d. Mortality is in the range of 50–60%despite ventilatory support
e. Idiopathic ARDS is synonymous with acute interstitial
pneumonia
5. Select the statement which best applies to non-speciﬁc inter-
stitial pneumonia:
a. The prognosis is similar to IPFb. Ground glass attenuation with minimal ﬁbrosis is the most
common radiological ﬁnding in the cellular variant
c. There is no known association of NSIP with connective
tissue diseases
d. A conﬁdent diagnosis can be made without lung biopsy
e. It is predominantly seen in elderly males with signiﬁcant
history of smoking
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